Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 January 2018 Photo Charl Devenish
Researcher tackling drug-resistant TB through molecular methods
Dr Anneke van der Spoel van Dijk is invested in contributing to the global effort of stopping TB by 2035.

The work of Dr Anneke van der Spoel van Dijk investigates the spread of TB in the Free State population using techniques such as next generation sequencing, spoligotyping and MIRU-VNTR typing. Dr Van der Spoel van Dijk, a senior medical scientist in the Department of Medical Microbiology at the University of the Free State (UFS) also looks at drug resistance in her research. This work informs decisions about how best to treat patients with multidrug-resistant TB (MDR-TB). 

She employs rapid molecular techniques to track one of Africa’s most serious diseases, tuberculosis (TB). 

Drug resistance
Scientists assist the National Health Laboratory Service and Department of Health in trying to refine the diagnostic tools to identify these cases earlier. Dr Van der Spoel van Dijk explains: “Until recently, it took up to two years to fine-tune treatment decisions for patients with MDR-TB. Patients get a cocktail of anti-TB drugs, but it takes time to find the right combination. Re-infection and relapse (patients stopping treatment for several reasons) add to the diagnostic and treatment management challenges.

Enormous impact
“Now doctors can reduce the time needed for diagnostic certainty to about seven days, while new drugs allow reduction of treatment from more than 18 to nine months. This can have an enormous impact on the life of many patients.”

Dr Van der Spoel van Dijk’s work forms part of research in the faculty looking at resistance development in TB strains. She is currently also doing her doctoral thesis on the differences and incidence of MDR-TB among adolescents versus adults. Dr Van der Spoel van Dijk says: “It is a complicated picture, but we hope to unravel it to support better diagnostic tools and patient care.”

As part of the National Health Laboratory Service, her department is playing an important role in TB diagnostics and the training of scientists and future pathologists. “Our work is contributing to the global vision to stop TB by 2035,” Dr Van der Spoel van Dijk says.

News Archive

‘Many people disagree with me. My life is One Long Debate.’ – Ali A. Mazrui
2014-10-31



Prof Ndlovu-Gatsheni
Photo: Stephen Collet
The Vice-Chancellor and Rector, in conjunction with the Centre for Africa Studies, recently presented a memorial lecture in honour of the work and life of an academic giant, the late Prof Ali A. Mazrui.

Ali Al'amin Mazrui (24 February 1933 – 12 October 2014), was an academic professor and political writer on African and Islamic studies. Hy was born in Mombasa, Kenya and was an Albert Schweitzer Professor in the Humanities, as well as Director of the Institute of Global Cultural Studies at Binghamton University, New York.

The lecture, held on Thursday 30 October 2014 in the Albert Wessels Auditiorium, was presented by Prof Sabelo J. Ndlovu-Gatsheni, Head of the Archie Mafeje Research Institute (AMRI) at UNISA.

His memorial lecture was entitled ‘Ali A Mazrui on the Invention of Africa and Postcolonial Predicaments’.

Prof Ndlovu-Gatsheni has published widely, including more than 47 articles in peer-reviewed journals, 45 chapters in books and 8 books. This includes The Ndebele Nation: Reflections on Hegemony, Memory and Historiography (Amsterdam & Pretoria: Rozenberg Publishers & UNISA Press, 2009), as well as Bondage of Boundaries and Identity Politics in Postcolonial Africa: The ‘Northern Problem’ and Ethno-Futures (Pretoria: Africa Institute of South Africa, 2013).

Prof Sabelo J Ndlovu-Gatsheni speech: ‘Ali A Mazrui on the Invention of Africa and Postcolonial Predicaments’.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept